The present invention provides pharmaceutical compounds for the treatment of high-grade superficial bladder cancer in patent in need thereof. Further described are compositions of azolium salts for use in such treatment.

The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.

In some aspects, the present disclosure provides compositions comprising an N4-based MMC ligand, a cell targeting group, and a fluorophore or a therapeutic compound comprising a formula: ##STR00001##
wherein the variables are as defined herein. In some embodiments, these compositions may be used in the imaging techniques or in the treatment of a disease or disorder such as cancer.

The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

The present invention provides compositions and methods for detecting tumor tissues in a subject. Embodiments of the present invention provide biocompatible chitosan nanoparticles suitable for dual modality optical imaging. Embodiments of the present invention provide methods for fabricating chitosan nanoparticles. Embodiments of the present invention provide methods for detecting tumor tissues in a subject using compositions provided by the present invention.

The present disclosure discloses methods and compositions for administering Cerenkov radiation-induced therapy (CRIT).

Disclosed are devices for detection of bleeding during surgical procedures and uses thereof. Also disclosed are methods of localizing a bleeding site during surgical procedures, and methods for evaluating an intensity of bleeding during the surgical procedures. The detection of bleeding is based, inter alia, on the presence of thrombin activity in a bleeding site.

The present disclosure relates to a system and a method for automatically measuring and assessing hemodynamics in tissue of an anatomical structure of a subject. In particular the present disclosure relates to continuously measuring and assessing hemodynamics in medical procedures using fluorescence imaging and wherein the administration of the fluorescent agent is controlled and automated. One aspect relates to a method of automatic perfusion assessment of an anatomical structure of a subject, the method comprising administration into a vein of a bolus corresponding to less than 0.005 mg ICG/kg body weight of a first fluorescence imaging agent. Another aspect relates to a system for automatic perfusion assessment of an anatomical structure during a medical procedure of a subject comprising a controllable injection pump for holding at least one first fluorescence imaging agent, the injection pump being configured for injecting a predefined amount of said first fluorescence imaging agent into the blood of the subject, wherein the system is configured for receiving and analysing a time series of fluorescence images of the tissue of said anatomical structure following the injection of the first fluorescence imaging agent, and determining at least one perfusion parameter of said anatomical structure based on said analysis.

A device for capturing an image of an object of medical interest in remitted or reflected illumination light and for capturing an image of the object in fluorescent light generated by Cy5.5 and/or SGM-101 and for capturing an image in fluorescent light generated OTL38 and/or indocyanine green (ICG). The device includes an image sensor for detecting blue, green and red light, another image sensor for detecting fluorescent light of Cy5.5 and/or SGM-101 and OTL38 and/or ICG, a beam splitter guiding light having a wavelength smaller than a predetermined cutoff wavelength to the first sensor and guiding light having a wavelength greater than the predetermined cutoff wavelength to the second sensor, and filters upstream of the second sensor for partially, substantially or completely suppressing light having a wavelength exciting Cy5.5 and/or SGM-101 and for partially, substantially or completely suppressing light having a wavelength suitable for exciting fluorescence of OTL38 and/or ICG.

The present disclosure describes a method for detecting and treating a low grade malignant tissue in a subject, comprising administering 5-aminolevulinic acid or a pharmaceutically acceptable salt or ester thereof, to the subject and measuring the fluorescence of the tissue.